You are here:
ELEVATED PLASMA TRANSFORMING GROWTH FACTOR-B1 LEVELS IN BREASTCANCER PATIENTS DECREASE AFTER SURGICAL REMOVAL OF THE TUMOR
Citation:
Kong, F., M. Anscher, T. Murase, B. Abbott, M. Iglehart, AND R. Jirtle. ELEVATED PLASMA TRANSFORMING GROWTH FACTOR-B1 LEVELS IN BREASTCANCER PATIENTS DECREASE AFTER SURGICAL REMOVAL OF THE TUMOR. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/J-95/475.
Description:
In breast cancer patients treated with high-dose chemotherapy followed by autologous bone marrow transplantation increased plasma TGFB levels are predictive for the occurrence of normal tissue complications (Anscher et al. EJM 328:1592-1598, 1993). n this investigation, we have determined whether breast tumors elevate plasma TGFB. n enzyme linked immunosorbent assay was used to measure plasma TGFB levels in 26 newly diagnosed breast cancer patients before and after definitive surgery. atients were grouped by postoperative tumor status: 1) negative lymph nodes (Group 1); 2) positive lymph nodes (Group 2); and 3) overt residual disease (Group 3). he site of TGFB production in the tumors was localized by immunohistochemistry and in situ hybridization. lasma TGFB levels were elevated preoperative in 81% of the patients; TGFB2 and TGFB were undetectable. he preoperative TGFB1 levels in the 3 patient groups were similar, however, the postoperative plasma TGFB1 levels differed by disease status. he mean plasma TGFB1 level in Group 1 (n=12) normalized after surgery (19.3+/-3.2 versus 5.5+1.00 ng/ml, p<0.001). In contrast, the mean plasma TGFB1 levels remained above normal in both Group 2 (n=9) and Group 3 (n=5) following surgery. GFB1 expression was found to be preferentially increased in the tumor stroma. reast tumors result in the plasma TGFB1 levels being increased in a majority of patients. herefore, TGFB1 may be a useful plasma marker for detecting breast tumors and following their response during therapy.